Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus

Sachin Wani, Gary W. Falk, Jane Post, Lisa Yerian, Matthew Hall, Amy Wang, Neil Gupta, Srinivas Gaddam, Mandeep Singh, Vikas Singh, Kengyu Chuang, Vikram Boolchand, Hemanth Gavini, John Kuczynski, Priti Sud, Ajay Bansal, Amit Rastogi, Sharad C. Mathur, Patrick Young, Brooks CashJohn Goldblum, David Lieberman, Richard E. Sampliner, Prateek Sharma

Research output: Contribution to journalArticle

158 Citations (Scopus)

Abstract

Background & Aims: Data vary on the progression of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE); in patients with LGD, we investigated the incidence of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) and compared progression in patients with different forms of LGD (prevalent vs incident and multifocal vs unifocal). We assessed the effects of consensus diagnosis of LGD on progression rates to HGD and EAC among expert pathologists. Methods: In a multicenter outcomes project, 210 patients with BE and LGD (classified as incident, prevalent, or persistent) were included. Patients were followed up for an average of 6.2 years (959.6 patient-years). Persistent LGD was defined as detection of LGD on 1 level). Histology specimens were reviewed by 2 blinded pathologists. Results: Six patients developed EAC (incidence of 0.44%/year), and 21 developed HGD (incidence of 1.6%/year). The incidence of the combination of HGD and EAC was 1.83%/year. There were no associations between presence of prevalent, incident, or persistent LGD and the extent of LGD with progression rates. Based on consensus diagnosis of 88 reviewed specimens, there was no difference in the progression of LGD to either EAC (the incidence based on analyses by the local pathologist was 0.18%/year, the incidence when there was agreement between the local and one central pathologist was 0.21%/year, and the incidence when all 3 pathologists were in agreement was 0.39%/year) or combined HGD and EAC (0.94%/year, 0.87%/year, and 0.84%/year, respectively). Conclusions: Overall, patients with BE and LGD have a low annual incidence of EAC, similar to nondysplastic BE. There are no risk factors for progression and there is significant interobserver variation in diagnosis, even among expert pathologists.

Original languageEnglish (US)
JournalGastroenterology
Volume141
Issue number4
DOIs
StatePublished - Oct 2011

Fingerprint

Barrett Esophagus
Adenocarcinoma
Incidence
Observer Variation
Pathologists
Histology

Keywords

  • Cancer
  • Esophagus
  • Natural History
  • Pathology Analysis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Wani, S., Falk, G. W., Post, J., Yerian, L., Hall, M., Wang, A., ... Sharma, P. (2011). Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology, 141(4). https://doi.org/10.1053/j.gastro.2011.06.055

Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. / Wani, Sachin; Falk, Gary W.; Post, Jane; Yerian, Lisa; Hall, Matthew; Wang, Amy; Gupta, Neil; Gaddam, Srinivas; Singh, Mandeep; Singh, Vikas; Chuang, Kengyu; Boolchand, Vikram; Gavini, Hemanth; Kuczynski, John; Sud, Priti; Bansal, Ajay; Rastogi, Amit; Mathur, Sharad C.; Young, Patrick; Cash, Brooks; Goldblum, John; Lieberman, David; Sampliner, Richard E.; Sharma, Prateek.

In: Gastroenterology, Vol. 141, No. 4, 10.2011.

Research output: Contribution to journalArticle

Wani, S, Falk, GW, Post, J, Yerian, L, Hall, M, Wang, A, Gupta, N, Gaddam, S, Singh, M, Singh, V, Chuang, K, Boolchand, V, Gavini, H, Kuczynski, J, Sud, P, Bansal, A, Rastogi, A, Mathur, SC, Young, P, Cash, B, Goldblum, J, Lieberman, D, Sampliner, RE & Sharma, P 2011, 'Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus', Gastroenterology, vol. 141, no. 4. https://doi.org/10.1053/j.gastro.2011.06.055
Wani, Sachin ; Falk, Gary W. ; Post, Jane ; Yerian, Lisa ; Hall, Matthew ; Wang, Amy ; Gupta, Neil ; Gaddam, Srinivas ; Singh, Mandeep ; Singh, Vikas ; Chuang, Kengyu ; Boolchand, Vikram ; Gavini, Hemanth ; Kuczynski, John ; Sud, Priti ; Bansal, Ajay ; Rastogi, Amit ; Mathur, Sharad C. ; Young, Patrick ; Cash, Brooks ; Goldblum, John ; Lieberman, David ; Sampliner, Richard E. ; Sharma, Prateek. / Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. In: Gastroenterology. 2011 ; Vol. 141, No. 4.
@article{066fac80c30145da9e0e39d8f46bf6af,
title = "Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus",
abstract = "Background & Aims: Data vary on the progression of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE); in patients with LGD, we investigated the incidence of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) and compared progression in patients with different forms of LGD (prevalent vs incident and multifocal vs unifocal). We assessed the effects of consensus diagnosis of LGD on progression rates to HGD and EAC among expert pathologists. Methods: In a multicenter outcomes project, 210 patients with BE and LGD (classified as incident, prevalent, or persistent) were included. Patients were followed up for an average of 6.2 years (959.6 patient-years). Persistent LGD was defined as detection of LGD on 1 level). Histology specimens were reviewed by 2 blinded pathologists. Results: Six patients developed EAC (incidence of 0.44{\%}/year), and 21 developed HGD (incidence of 1.6{\%}/year). The incidence of the combination of HGD and EAC was 1.83{\%}/year. There were no associations between presence of prevalent, incident, or persistent LGD and the extent of LGD with progression rates. Based on consensus diagnosis of 88 reviewed specimens, there was no difference in the progression of LGD to either EAC (the incidence based on analyses by the local pathologist was 0.18{\%}/year, the incidence when there was agreement between the local and one central pathologist was 0.21{\%}/year, and the incidence when all 3 pathologists were in agreement was 0.39{\%}/year) or combined HGD and EAC (0.94{\%}/year, 0.87{\%}/year, and 0.84{\%}/year, respectively). Conclusions: Overall, patients with BE and LGD have a low annual incidence of EAC, similar to nondysplastic BE. There are no risk factors for progression and there is significant interobserver variation in diagnosis, even among expert pathologists.",
keywords = "Cancer, Esophagus, Natural History, Pathology Analysis",
author = "Sachin Wani and Falk, {Gary W.} and Jane Post and Lisa Yerian and Matthew Hall and Amy Wang and Neil Gupta and Srinivas Gaddam and Mandeep Singh and Vikas Singh and Kengyu Chuang and Vikram Boolchand and Hemanth Gavini and John Kuczynski and Priti Sud and Ajay Bansal and Amit Rastogi and Mathur, {Sharad C.} and Patrick Young and Brooks Cash and John Goldblum and David Lieberman and Sampliner, {Richard E.} and Prateek Sharma",
year = "2011",
month = "10",
doi = "10.1053/j.gastro.2011.06.055",
language = "English (US)",
volume = "141",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus

AU - Wani, Sachin

AU - Falk, Gary W.

AU - Post, Jane

AU - Yerian, Lisa

AU - Hall, Matthew

AU - Wang, Amy

AU - Gupta, Neil

AU - Gaddam, Srinivas

AU - Singh, Mandeep

AU - Singh, Vikas

AU - Chuang, Kengyu

AU - Boolchand, Vikram

AU - Gavini, Hemanth

AU - Kuczynski, John

AU - Sud, Priti

AU - Bansal, Ajay

AU - Rastogi, Amit

AU - Mathur, Sharad C.

AU - Young, Patrick

AU - Cash, Brooks

AU - Goldblum, John

AU - Lieberman, David

AU - Sampliner, Richard E.

AU - Sharma, Prateek

PY - 2011/10

Y1 - 2011/10

N2 - Background & Aims: Data vary on the progression of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE); in patients with LGD, we investigated the incidence of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) and compared progression in patients with different forms of LGD (prevalent vs incident and multifocal vs unifocal). We assessed the effects of consensus diagnosis of LGD on progression rates to HGD and EAC among expert pathologists. Methods: In a multicenter outcomes project, 210 patients with BE and LGD (classified as incident, prevalent, or persistent) were included. Patients were followed up for an average of 6.2 years (959.6 patient-years). Persistent LGD was defined as detection of LGD on 1 level). Histology specimens were reviewed by 2 blinded pathologists. Results: Six patients developed EAC (incidence of 0.44%/year), and 21 developed HGD (incidence of 1.6%/year). The incidence of the combination of HGD and EAC was 1.83%/year. There were no associations between presence of prevalent, incident, or persistent LGD and the extent of LGD with progression rates. Based on consensus diagnosis of 88 reviewed specimens, there was no difference in the progression of LGD to either EAC (the incidence based on analyses by the local pathologist was 0.18%/year, the incidence when there was agreement between the local and one central pathologist was 0.21%/year, and the incidence when all 3 pathologists were in agreement was 0.39%/year) or combined HGD and EAC (0.94%/year, 0.87%/year, and 0.84%/year, respectively). Conclusions: Overall, patients with BE and LGD have a low annual incidence of EAC, similar to nondysplastic BE. There are no risk factors for progression and there is significant interobserver variation in diagnosis, even among expert pathologists.

AB - Background & Aims: Data vary on the progression of low-grade dysplasia (LGD) in patients with Barrett's esophagus (BE); in patients with LGD, we investigated the incidence of high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) and compared progression in patients with different forms of LGD (prevalent vs incident and multifocal vs unifocal). We assessed the effects of consensus diagnosis of LGD on progression rates to HGD and EAC among expert pathologists. Methods: In a multicenter outcomes project, 210 patients with BE and LGD (classified as incident, prevalent, or persistent) were included. Patients were followed up for an average of 6.2 years (959.6 patient-years). Persistent LGD was defined as detection of LGD on 1 level). Histology specimens were reviewed by 2 blinded pathologists. Results: Six patients developed EAC (incidence of 0.44%/year), and 21 developed HGD (incidence of 1.6%/year). The incidence of the combination of HGD and EAC was 1.83%/year. There were no associations between presence of prevalent, incident, or persistent LGD and the extent of LGD with progression rates. Based on consensus diagnosis of 88 reviewed specimens, there was no difference in the progression of LGD to either EAC (the incidence based on analyses by the local pathologist was 0.18%/year, the incidence when there was agreement between the local and one central pathologist was 0.21%/year, and the incidence when all 3 pathologists were in agreement was 0.39%/year) or combined HGD and EAC (0.94%/year, 0.87%/year, and 0.84%/year, respectively). Conclusions: Overall, patients with BE and LGD have a low annual incidence of EAC, similar to nondysplastic BE. There are no risk factors for progression and there is significant interobserver variation in diagnosis, even among expert pathologists.

KW - Cancer

KW - Esophagus

KW - Natural History

KW - Pathology Analysis

UR - http://www.scopus.com/inward/record.url?scp=80053601891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053601891&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2011.06.055

DO - 10.1053/j.gastro.2011.06.055

M3 - Article

C2 - 21723218

AN - SCOPUS:80053601891

VL - 141

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 4

ER -